Scalper1 News
Juno Therapeutics’ (JUNO) stock rebounded Tuesday as the company reported “highly encouraging” results from a clinical trial on pediatric patients with leukemia, after shares fell sharply Monday. Juno is developing cellular immunotherapies to treat leukemia and lymphoma, using what is called CAR-T therapies, short for chimeric antigen receptor T-cell therapy. CAR-T uses human T-cells as therapeutics to recognize and kill cancer cells, with the Scalper1 News
Scalper1 News